首页> 外国专利> CORNEAL COLLAGEN CROSSLINKING AND SIMULTANEOUS IMPLANTATION OF INTRASTROMAL CORNEAL SEGMENTS IN THE PAIRED EYE IN PATIENTS WITH DIFFERENT STAGES OF KERATOCONUS

CORNEAL COLLAGEN CROSSLINKING AND SIMULTANEOUS IMPLANTATION OF INTRASTROMAL CORNEAL SEGMENTS IN THE PAIRED EYE IN PATIENTS WITH DIFFERENT STAGES OF KERATOCONUS

机译:角膜胶原交联和同时植入角质胶质术阶段配对眼中的细胞内角膜段

摘要

FIELD: medicine. ;SUBSTANCE: invention relates to medicine, namely to ophthalmology. Cross-linking is performed only on one eye, while intrastromal corneal segments are implanted simultaneously on the paired eye, and the treatment of the operating field and the instillation of antibacterial and anesthetic drops are carried out on both eyes simultaneously for 2-3 minutes. Then, on the first eye, de-epithelialization of the cornea with a diameter of 8.5 mm is performed for 1 minute. Then, for 30 minutes on the first eye, the stroma is impregnated with a 0.1% solution of riboflavin mononucleotide and dextran by instillations 1 time per minute for 30 minutes. At the same time, a 360° intrastromal corneal tunnel is formed on the paired eye by femtodissection of the corneal stroma at a depth of 80% of the corneal thickness. An entrance incision is also formed for the introduction of an intrastromal corneal segment, and a 1.0-1.3 mm long incision is made perpendicular to the formed corneal tunnel, asymmetrically from the planned installation of the corneal segment, and the corneal segment is installed so that its edges are as far as possible from the zone of the entrance incisions. After that, in the next 30 minutes, the cornea of ​​the eye is irradiated with ultraviolet light on the first eye, and a riboflavin solution is instilled with a frequency of 1 every 3-5 minutes. The operation ends with the imposition of soft contact lenses.;EFFECT: method increases the efficiency of treatment of a patient with different degrees of keratoconus while reducing the duration of treatment and ensures safety and convenience for the ophthalmic surgeon.;1 cl, 3 ex
机译:领域:医学。物质:发明涉及药物,即眼科。仅在一只眼睛上进行交联,而在双眼上同时植入具有细胞内角膜段的同时植入操作场和抗菌和麻醉下降的滴注同时进行2-3分钟。然后,在第一眼上,进行直径为8.5mm的角膜的去上皮化1分钟。然后,在第一眼睛上30分钟,通过滴注每分钟滴注101%的核黄素单核苷酸和葡聚糖溶液30分钟。同时,通过毫微微缩小的角膜基质在角膜厚度的深度的深度为80%的纤维化术中形成了360°的细胞内角膜隧道。还形成了用于引入科内角膜段的入口切口,并且1.0-1.3毫米长的切口垂直于形成的角膜隧道,从计划安装的角膜段的安装,并且角膜段是这样的它的边缘尽可能来自入口切口区域。之后,在接下来的30分钟中,用第一眼的紫外线照射眼的角膜,核黄素溶液每3-5分钟滴注1次频率。该操作以施加柔软的隐形眼镜结束。;效果:方法提高了不同程度的角蛋白的患者的治疗效率,同时减少了治疗的持续时间,确保了眼科外科医生的安全性和便利性。; 1 cl,3 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号